Cash, cash equivalents and marketable securities as of June 30 were $825.1M. Cerevel’s cash, cash equivalents, and marketable securities are expected to support all planned data readouts in 2024 and fund operations into 2025. “The science and innovation at Cerevel are extraordinary, matched only by the passion and dedication of the team I’ve had the honor to get to know over the last two months,” said Ron Renaud, president and CEO of Cerevel Therapeutics. “We remain focused on execution as we prepare for a pivotal year in 2024 with data from multiple late-stage clinical trials in schizophrenia, epilepsy, and Parkinson’s disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE:
- Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
- Cerevel Therapeutics Holdings Inc (CERE) Q2 Earnings Cheat Sheet
- Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
- Cerevel Therapeutics director Dekkers sells 200,000 common shares
- Cerevel Therapeutics names Paul Burgess Chief Business Development Officer
